Rasagiline

Monoamine Oxidase Inhibitor — NERVOUS SYSTEM

Key facts

Rasagiline is an ofp drug in the Monoamine Oxidase Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2005. Its mechanism of action is classified as Monoamine Oxidase Inhibitors. DrugCentral lists 7 molecular targets, including HTR6, Maob and ACHE. Recorded indications include Parkinson's disease.

• Approval status: ofp (first approved 2005 by the EMA).
• Drug class: Monoamine Oxidase Inhibitor.
• Mechanism of action: Monoamine Oxidase Inhibitors.
• Molecular targets: HTR6, Maob, ACHE and Maoa (7 listed in DrugCentral).
• Indications: Parkinson's disease.
• ATC code: N04BD02 (Monoamine oxidase B inhibitors).
• Molecular formula: C12H13N; molecular weight 171.24 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Parkinson's disease

Contraindications (8)

• Bipolar disorder
• Disease of liver
• Dyskinesia
• Epilepsy
• Hypertensive disorder
• Malignant melanoma
• Orthostatic hypotension
• Pheochromocytoma

Mechanism & targets

• Mechanism of action (MoA): Monoamine Oxidase Inhibitors
• Established pharmacologic class: Monoamine Oxidase Inhibitor

Molecular targets (7)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 8.85
Amine oxidase [flavin-containing] B	Maob	unknown	IC50 8.36
Acetylcholinesterase	ACHE	unknown	IC50 7.72
Amine oxidase [flavin-containing] A	Maoa	unknown	IC50 6.39
Amine oxidase [flavin-containing] B	MAOB	inhibitor	Ki 6.15
Cholinesterase	BCHE	unknown	IC50 5.32
Amine oxidase [flavin-containing] A	MAOA	unknown	Ki 5.01

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2018-03-23	PMDA	—	Takeda Pharmaceutical Company Limited
2006-05-16	FDA	—	TEVA
2005-02-21	EMA	—	TEVA B.V.

ATC classification

ATC code	Therapeutic hierarchy
N04BD02	NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Monoamine oxidase B inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hallucination	971.2
Dyskinesia	845.2
On and off phenomenon	512.1
Hallucination, visual	487.4
Impulse-control disorder	452.3
Fall	363.2
Freezing phenomenon	343.1
Serotonin syndrome	335.3
Hypersexuality	323.2
Gambling disorder	274.9
Orthostatic hypotension	268.5
Tremor	215.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Rasagiline is on its molecule page.

• Molecular formula: C₁₂H₁₃N
• Molecular weight: 171.24 g/mol
• CAS number: 136236-51-6
• InChIKey: RUOKEQAAGRXIBM-GFCCVEGCSA-N
• PubChem CID: 3052776

C#CCN[C@@H]1CCC2=C1C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rasagiline used for?

DrugCentral lists the following indications for Rasagiline: Parkinson's disease.

How does Rasagiline work?

Rasagiline is classified as Monoamine Oxidase Inhibitors; its molecular targets in DrugCentral include HTR6, Maob, ACHE and Maoa.

When was Rasagiline first approved?

Rasagiline was first approved by the EMA in 2005.

What drug class does Rasagiline belong to?

Rasagiline is in the Monoamine Oxidase Inhibitor class.

What is the chemical formula of Rasagiline?

Rasagiline has the molecular formula C12H13N and a molecular weight of 171.24 g/mol.

Sources

• DrugCentral drug card 3521 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201142 — compound record and bioactivity
• PubChem CID 3052776 — chemical identifiers
• DrugBank DB01367 — drug record
• FDA UNII 003N66TS6T — substance identity
• DailyMed: FDA labels for Rasagiline — current prescribing information (label search)
• UniProt P50406 (HTR6) — target protein
• UniProt P22303 (ACHE) — target protein
• UniProt P27338 (MAOB) — target protein
• UniProt P06276 (BCHE) — target protein
• UniProt P21397 (MAOA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.